{
  "name": "RedFlag Index Q3 2026",
  "publisher": "The Precedent",
  "url": "https://theprecedent.org/red-flag-index",
  "asOf": "2026-11-18",
  "scale": "0-100, higher is worse",
  "bands": {
    "80-100": "Critical",
    "60-79": "Elevated",
    "40-59": "Moderate",
    "0-39": "Lower"
  },
  "companies": [
    {
      "rank": 1,
      "ticker": "PFE",
      "exchange": "NYSE",
      "company": "Pfizer Inc.",
      "score": 84,
      "cases": 7,
      "open": 4,
      "profile": "https://theprecedent.org/company/pfizer",
      "summary": "Pfizer has paid about $11.3 billion in tracked penalties since 2000.\n\n2025: Pfizer and Tris Pharma agreed to pay Texas $41.5 million over allegations they supplied adulterated ADHD drug Quillivant to Medicaid.\n\n2024: Independent drug-pricing watchdog ICER rated Vyndamax \"low\" value and said a fair price would be $13,600–$39,000 a year, an 85–95% cut.\n\n2016: Pfizer subsidiary Wyeth paid $784.6 million to resolve False Claims Act allegations of underpaying Medicaid rebates on Protonix.\n\n2009: Pfizer paid $2.3 billion for off-label promotion and kickbacks on Bextra, Geodon, Zyvox, and Lyrica. This included a $1.195 billion criminal fine, then the largest in U.S. history.\n\n2004: Warner-Lambert, acquired by Pfizer in 2000, paid $430 million over off-label promotion of Neurontin."
    },
    {
      "rank": 2,
      "ticker": "CVS",
      "exchange": "NYSE",
      "company": "CVS Health Corporation",
      "score": 81,
      "cases": 7,
      "open": 5,
      "profile": "https://theprecedent.org/company/cvs-health",
      "summary": "December 2025: CVS paid $37.76 million under the False Claims Act for over-dispensing insulin pens, and admitted certain conduct.\n\n2025: Omnicare, a CVS Health subsidiary, was hit with a $948.8 million judgment after a jury found more than 3.3 million false claims from 2010 to 2018.\n\nDecember 2024: The DOJ sued CVS, alleging unlawful opioid dispensing since October 2013. The case is pending.\n\n2022–2023: CVS agreed to pay about $5 billion over 10 years in the national opioid settlement.\n\n2022: CVS paid Florida $484 million in a separate opioid settlement.\n\n2020: Omnicare, a CVS Health subsidiary, paid $15.3 million for Controlled Substances Act violations."
    },
    {
      "rank": 3,
      "ticker": "ABBV",
      "exchange": "NYSE",
      "company": "AbbVie Inc.",
      "score": 70,
      "cases": 6,
      "open": 3,
      "profile": "https://theprecedent.org/company/abbvie",
      "summary": "AbbVie has paid more than $7.5 billion in tracked penalties since 2000, including Abbott-era matters.\n\n2025: AbbVie paid Oregon $9.25 million over AndroGel marketing.\n\n2023: AbbVie paid $2.7 million to settle Humira kickback allegations.\n\n2022: Allergan, an AbbVie subsidiary, agreed to pay up to $2.37 billion in a nationwide opioid settlement.\n\n2020: AbbVie paid California $24 million over Humira marketing allegations."
    },
    {
      "rank": 4,
      "ticker": "MCK",
      "exchange": "NYSE",
      "company": "McKesson Corporation",
      "score": 67,
      "cases": 3,
      "open": 1,
      "profile": "https://theprecedent.org/company/mckesson",
      "summary": "McKesson's opioid-related penalties total about $8.7 billion.\n\n2022: McKesson agreed to pay up to $7.4 billion over 18 years in the national opioid distributor settlement.\n\n2022: RxPak, a McKesson subsidiary, paid $1 million over more than 700 alleged controlled-substance record-keeping violations.\n\n2017: McKesson paid $150 million, then a record for a distributor, for Controlled Substances Act violations. Controlled-substance shipments from four McKesson distribution centers were suspended.\n\nMcKesson's Colorado distribution center processed more than 1.6 million controlled-substance orders from 2008 to 2013 and reported only 16 as suspicious.\n\n2008: McKesson paid $13.25 million for Controlled Substances Act violations."
    },
    {
      "rank": 5,
      "ticker": "JNJ",
      "exchange": "NYSE",
      "company": "Johnson & Johnson",
      "score": 62,
      "cases": 4,
      "open": 3,
      "profile": "https://theprecedent.org/company/johnson-and-johnson",
      "summary": "Johnson & Johnson has paid about $25.1 billion in tracked penalties since 2000, the highest in this set.\n\n2024: Johnson & Johnson paid $700 million to 42 states and D.C. over talc marketing.\n\n2021–2022: Janssen, a Johnson & Johnson subsidiary, agreed to pay up to $5 billion in the national opioid settlement.\n\n2021: Johnson & Johnson recorded about $800 million to resolve roughly 9,000 Risperdal gynecomastia cases.\n\n2013: Johnson & Johnson paid $2.2 billion over Risperdal, Invega, and Natrecor, including about $485 million in criminal fines and forfeiture.\n\n2013: DePuy, a Johnson & Johnson subsidiary, agreed to a $2.5 billion hip-implant settlement."
    },
    {
      "rank": 6,
      "ticker": "CI",
      "exchange": "NYSE",
      "company": "The Cigna Group / Express Scripts",
      "score": 57,
      "cases": 4,
      "open": 3,
      "profile": "https://theprecedent.org/company/cigna-express-scripts",
      "summary": "2023: Cigna paid $172.3 million under the False Claims Act for submitting inaccurate Medicare Advantage diagnosis codes, with factual admissions.\n\nCigna is under a five-year corporate integrity agreement until about September 2028."
    },
    {
      "rank": 7,
      "ticker": "BMY",
      "exchange": "NYSE",
      "company": "Bristol-Myers Squibb Company",
      "score": 57,
      "cases": 4,
      "open": 2,
      "profile": "https://theprecedent.org/company/bristol-myers-squibb",
      "summary": "Bristol-Myers Squibb has paid about $3.0 billion in tracked penalties since 2000 across 52 records. About $956 million of that is for competition-related violations.\n\n2025: Bristol-Myers Squibb paid Hawaii $350 million over Plavix labeling and marketing. Sanofi paid the same amount.\n\n2009: Bristol-Myers Squibb paid the FTC $2.1 million, the maximum then allowed, for hiding a Plavix patent side deal.\n\n2007: Bristol-Myers Squibb paid $515.5 million over Abilify off-label promotion, kickbacks, and pricing."
    },
    {
      "rank": 8,
      "ticker": "LLY",
      "exchange": "NYSE",
      "company": "Eli Lilly and Company",
      "score": 55,
      "cases": 6,
      "open": 3,
      "profile": "https://theprecedent.org/company/eli-lilly",
      "summary": "Eli Lilly has paid about $3.0 billion in tracked penalties since 2000.\n\nSeptember 2026: Florida sued Eli Lilly, alleging it set Humalog's list price at about $280 a vial while returning about $210 to PBMs as rebates. The suit alleges uninsured patients pay the full list price. The case is unresolved.\n\nThe same complaint says Eli Lilly, Novo Nordisk, and Sanofi supply more than 90% of the world's insulin.\n\n2009: Eli Lilly paid $1.415 billion over Zyprexa, including a $515 million criminal fine.\n\n2005: Eli Lilly paid $36 million over Evista, including a $6 million criminal fine."
    },
    {
      "rank": 9,
      "ticker": "AMGN",
      "exchange": "NASDAQ",
      "company": "Amgen Inc.",
      "score": 42,
      "cases": 3,
      "open": 2,
      "profile": "https://theprecedent.org/company/amgen",
      "summary": "2019: Amgen paid $24.75 million over allegations that its copay-charity donations were kickbacks for Sensipar and Kyprolis.\n\n2015: Amgen paid $71 million to 48 states and D.C. over off-label marketing of Enbrel and Aranesp.\n\n2012: Amgen paid $762 million and pleaded guilty to misbranding Aranesp, including a $136 million criminal fine."
    },
    {
      "rank": 10,
      "ticker": "MRK",
      "exchange": "NYSE",
      "company": "Merck & Co., Inc.",
      "score": 36,
      "cases": 3,
      "open": 1,
      "profile": "https://theprecedent.org/company/merck",
      "summary": "Merck has paid more than $10.7 billion in tracked penalties since 2000.\n\n2011–2012: Merck paid $950 million and pleaded guilty to illegally promoting Vioxx, including a $321.6 million criminal fine.\n\n2008: Merck paid $650 million over pricing and kickback allegations involving Zocor, Vioxx, and Pepcid."
    }
  ]
}